Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. Zusätzlich bieten wir Ihnen PCSK9 Kits (74) und PCSK9 Proteine (64) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 160 products:
Human Polyclonal PCSK9 Primary Antibody für ChIP, IHC (p) - ABIN268772
Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. in Nature genetics 2005
Zeige alle 10 Referenzen für 268772
Human Polyclonal PCSK9 Primary Antibody für EIA, WB - ABIN453778
McNutt, Kwon, Chen, Chen, Horton, Lagace: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. in The Journal of biological chemistry 2009
Zeige alle 3 Referenzen für 453778
Human Polyclonal PCSK9 Primary Antibody für IHC, ELISA - ABIN185371
Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. in Journal of lipid research 2005
Zeige alle 2 Referenzen für 185371
Human Polyclonal PCSK9 Primary Antibody für FACS, IHC (p) - ABIN391505
Shioji, Mannami, Kokubo, Inamoto, Takagi, Goto, Nonogi, Iwai: Genetic variants in PCSK9 affect the cholesterol level in Japanese. in Journal of human genetics 2004
Zeige alle 2 Referenzen für 391505
Human Polyclonal PCSK9 Primary Antibody für FACS, IHC (p) - ABIN652320
Abifadel, Varret, Rabès, Allard, Ouguerram, Devillers, Cruaud, Benjannet, Wickham, Erlich, Derré, Villéger, Farnier, Beucler, Bruckert, Chambaz, Chanu, Lecerf, Luc, Moulin, Weissenbach, Prat, Krempf et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. ... in Nature genetics 2003
Zeige alle 2 Referenzen für 652320
Human Polyclonal PCSK9 Primary Antibody für IF (p), IHC (p) - ABIN761831
Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. in Molecular medicine reports 2016
Human Polyclonal PCSK9 Primary Antibody für EIA, WB - ABIN569616
Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. in Proceedings of the National Academy of Sciences of the United States of America 2008
Use Crispr-Cas (zeige CSE1L Antikörper) system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels.
PCSK9 decreased in youth participating in an intensive dietary intervention. Change in HOMA-IR was associated with change in PCSK9, independent of weight loss, suggesting an important relationship with insulin (zeige INS Antikörper) sensitivity.
these studies support that reductions in Lp(a (zeige APOA Antikörper)) with PCSK9 inhibition are partly due to increased LDLR (zeige LDLR Antikörper)-mediated uptake. In most situations, Lp(a (zeige APOA Antikörper)) appears to compete poorly with LDL for LDLR (zeige LDLR Antikörper) binding and internalization, but when LDLR (zeige LDLR Antikörper) expression is increased with evolocumab, particularly in the setting of low circulating LDL, Lp(a (zeige APOA Antikörper)) is reduced.
Plasma levels of proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C-III (apoC3 (zeige APOC3 Antikörper)) and small dense low density lipoprotein cholesterol (sdLDL-C) showed significant interactions with current dyslipidemias, and were predictive in the screening.
Some loss of function variants in PCSK9 are associated with enhanced LDL cholesterol lowering response to statin therapy.
These observations suggest positive feedback interplay between SMC (zeige DYM Antikörper)-derived PCSK9 and mtDNA damage in the proinflammatory milieu involving mtROS. This interaction results in cellular injury, characterized by apoptosis-a hallmark of atherosclerosis.
PCSK9 level is not associated with systolic or diastolic blood pressure in hypertensives or normotensives, but it positively correlates with carotid intima-media thickness in hypertensives in univariate but not multivariate analyses, and further researches are needed.
results reveal that the tanshinone IIA modulates LDLR (zeige LDLR Antikörper) level and activity via down-regulation of PCSK9 expression in hepatic cells
This article reviews the functions and regulatory mechanisms of PCSK9. The effects of PCSK9 on the LDL receptor (zeige LDLR Antikörper), the relationship of this convertase with IDOL (zeige MYLIP Antikörper), and treatments currently available against hypercholesterolemia are also discussed. [review]
LC n-3 PUFA intake is associated with a lower risk of nonfatal MI in C-allele carriers of PCSK9 rs11206510 (n = 799) but not in non-C-allele carriers (n = 3188).
Use Crispr-Cas (zeige CTNND1 Antikörper) system to introduce nonsense variants into PCSK9 to lower blood cholesterol levels.
Studied the combination model of a single AAV-PCSK9 injection, high-fat diet, and partial carotid ligation which induces robust atherosclerosis in the flow-disturbed carotid artery within 3 weeks in C57 mice, and results suggest this is a quick and convenient model to study atherosclerosis and mechanisms using any knockout or transgenic mice without having to generate double knockouts.
AdipoR activation by agonists regulated PCSK9 expression and inhibits atherosclerosis in apoE (zeige APOE Antikörper)(-/-) mice.
Adeno (zeige ADORA2A Antikörper)-associated virus mediated infection with a mouse PCSK9 gain-of-function mutation is a rapid, easy, and efficient approach for inducing hypercholesterolemia and promoting abdominal aortic aneurysms in C57BL/6 mice infused with angiotensin II.
conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2 (zeige CA2 Antikörper)+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR (zeige LDLR Antikörper) degradation and promoting LDLR (zeige LDLR Antikörper)-dependent hepatic cholesterol uptake.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor (zeige LDLR Antikörper) Degradation.
PCSK9 increases hepatic lipid and lipoprotein production via apoE (zeige APOE Antikörper)- and LDLR (zeige LDLR Antikörper)-dependent mechanisms
Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating PCSK9.
This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
proprotein convertase subtilisin/kexin type 9
, convertase subtilisin/kexin type 9 preproprotein
, neural apoptosis regulated convertase 1
, subtilisin/kexin-like protease PC9
, convertase subtilisin
, neural apoptosis-regulated convertase 1
, proprotein convertase 9
, proprotein convertase PC9
, proprotein convertase subtilisin/kexin type 9 preproprotein
, Proprotein convertase 9
, Subtilisin/kexin-like protease PC9